ArticleJournal of cardiothoracic surgery2026
Postoperative magnesium sulfate and atrial fibrillation after coronary artery bypass grafting: a single-center retrospective comparative cohort study.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative atrial fibrillation (POAF) is a common complication following coronary artery bypass grafting (CABG). Magnesium sulfate has been evaluated as a preventive strategy. This study investigated whether early postoperative magnesium supplementation is associated with reduced new-onset POAF, shorter hospital length of stay (LOS), lower incidence of premature ventricular contractions (PVCs), and less postoperative surgical bleeding after on-pump CABG.
methodsWe conducted a quantitative, retrospective, single-center, comparative cohort study at the Specialized Arab Hospital (Nablus, Palestine). Consecutively sampled adults undergoing first-time elective on-pump CABG between January 2021 and December 2023 were included (N = 220). Per an institutional, serum-triggered (threshold-based) protocol, 108 patients received intravenous magnesium sulfate (MgSO₄) within the first 48 postoperative hours; 112 did not. Exploratory adjusted analyses were also performed for POAF and LOS using available demographic and operative covariates.
resultsThe incidence of POAF was significantly lower in the MgSO₄ group (11.1%) than in the No MgSO₄ group (78.6%) (p < 0.0001). MgSO₄ was also associated with a shorter LOS (5.26 ± 0.44 vs. 5.51 ± 0.71 days; p = 0.002). Postoperative surgical bleeding was lower with borderline significance in the MgSO₄ group (2.73% vs. 9.55%; p = 0.050). The incidence of PVCs was lower with MgSO₄ (5.91% vs. 20.0%; p = 0.002). In exploratory adjusted analyses, MgSO₄ exposure remained independently associated with lower odds of POAF and shorter LOS.
conclusionThreshold-based postoperative magnesium sulfate administered within the first 48 h after on-pump CABG surgery was associated with a reduced incidence of POAF, a shorter LOS, and fewer PVCs; the reduction in surgical bleeding was borderline. Exploratory adjusted analyses for POAF and LOS supported the robustness of these associations. These observational findings support prospective—ideally randomized—evaluation to confirm effectiveness and define optimal dosing and serum targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.